Spots Global Cancer Trial Database for cd40
Every month we try and update this database with for cd40 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer | NCT06205849 | Pancreatic Canc... | IRE + intratumo... NanoKnife | 18 Years - | University of California, San Diego | |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | NCT03123783 | Cancer Non Small Cell ... Metastatic Mela... Neoplasm of Lun... Melanoma | APX005M Nivolumab | 18 Years - | Apexigen America, Inc. | |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | NCT00670592 | Non-Hodgkin's L... Hodgkin's Lymph... | HCD122 | 18 Years - | Novartis | |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | NCT03123783 | Cancer Non Small Cell ... Metastatic Mela... Neoplasm of Lun... Melanoma | APX005M Nivolumab | 18 Years - | Apexigen America, Inc. | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | NCT04547777 | Glioma, Maligna... | D2C7-IT 2141-V11 | 18 Years - | Duke University | |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | NCT00670592 | Non-Hodgkin's L... Hodgkin's Lymph... | HCD122 | 18 Years - | Novartis | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | NCT04364230 | Melanoma Ocular Melanoma Uveal Melanoma | 6MHP NeoAg-mBRAF PolyICLC CDX-1140 | 18 Years - | University of Virginia | |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | NCT04547777 | Glioma, Maligna... | D2C7-IT 2141-V11 | 18 Years - | Duke University | |
| Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer | NCT06205849 | Pancreatic Canc... | IRE + intratumo... NanoKnife | 18 Years - | University of California, San Diego | |
| A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma | NCT04337931 | Unresectable Me... Metastatic Mela... Cancer Cancer of Skin Melanoma Melanoma (Skin) | sotigalimab | 18 Years - | Apexigen America, Inc. | |
| Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | NCT04364230 | Melanoma Ocular Melanoma Uveal Melanoma | 6MHP NeoAg-mBRAF PolyICLC CDX-1140 | 18 Years - | University of Virginia | |
| Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma | NCT01275209 | Follicular Lymp... | HCD122 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
